Emerging Biotechs: The Trailblazers of Drug Development
Emerging biotechs are a force to be reckoned with. In 2018, approximately 70% of clinical pipelines belonged to emerging biotechs, who were also responsible for nearly 64% of new active substances approved by the FDA. In other words, 38 out of 59 approved therapies were patented by emerging biotechs last year. These numbers prove that biotechs are leveling the playing field and are leading innovation in the drug discovery and development space.
As this space becomes increasingly crowded, companies will need to develop and differentiate their portfolio to be the real winners. Biotechs are confronted with various challenges, especially in the early, high-risk stages of compound development.
Challenges for Emerging Biotechs: What’s Keeping You Up at Night?
Rising drug development costs, a steadily accelerating race to collect impactful data, increasing knowledge of the epidemiology of diseases, growing competition for suitable trial sites, and a generally crowded market, are all factors that shape the highly competitive landscape of the life sciences industry.
“Biotech companies are working to develop treatments that haven’t been defined, with science that has yet to be tested, to treat diseases that we are only now beginning to understand. Working with these innovators and pioneers makes our work at Medpace incredibly exciting and fulfilling as we help to advance these novel medical therapies.”
Reinilde Heyrman, MD, Vice President of the Medical Department at Medpace
As a CRO dedicated to the support of emerging biotechs, Medpace takes pride in our clients’ work. As a partner, we share your passion for research and strive to help you achieve success.
Medpace and Biotechs
Labiotech, a leading digital media covering the European Biotech industry recently featured Medpace in their white paper, “A Toolkit for Emerging Biotechs: Practical Advice for Navigating Challenges and Advancing Clinical Development” Download the white paper now to learn more about about the challenges biotechs face with solutions to dominate and lead innovation in the industry.
